Know Cancer

or
forgot password

Pilot Study To Assess The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases


N/A
18 Years
N/A
Open (Enrolling)
Both
Gastro-enteropancreatic Neuroendocrine Tumor, Secondary Malignant Neoplasm of Liver

Thank you

Trial Information

Pilot Study To Assess The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases


Inclusion Criteria:



- Histopathologic evidence of well differentiated neuroendocrine tumor of
gastroenteropancreatic origin

- Evidence of metastatic disease of at least 2.0 cm in the liver by MRI or CT imaging.

- Patient ≥18 years of age on the day of signing informed consent.

Exclusion Criteria:

- Any contraindication to MRI based on departmental MR questionnaire

- Inability to cooperate for an MR exam

- Patient has a history of a second active malignancy with evidence of metastases.
Patients with a history of resected prior malignancy or one that would not interfere
with the MRI results is allowed.

- Patient has known psychiatric or substance abuse disorders that would, in the opinion
of the treating investigator, interfere with cooperation with the requirements of the
trial.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

reproducibility of diffusion weighted imaging for neuroendocrine liver metastases.

Outcome Description:

The investigators will calculate an ADC value for each metastasis that was chosen through consensus by the two participating radiologists. ADC is a voxel-level measurement so summary measures will be employed in order to get a single measurement for the ROI of each metastasis under study. For both the clinical and research MRI, the investigators will take the voxel-level data and calculate the mean, median, and minimum ADC within each ROI.

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Richard Kinh Gian Do, MD,PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

11-122

NCT ID:

NCT01423734

Start Date:

August 2011

Completion Date:

August 2014

Related Keywords:

  • Gastro-enteropancreatic Neuroendocrine Tumor
  • Secondary Malignant Neoplasm of Liver
  • ADRENAL GLAND
  • MRI
  • 11-122
  • Neoplasms
  • Liver Neoplasms
  • Neoplasm Metastasis
  • Neuroendocrine Tumors
  • Neoplasms, Second Primary
  • Intestinal Neoplasms
  • Pancreatic Neoplasms
  • Stomach Neoplasms

Name

Location

Memorial Sloan Kettering Cancer CenterNew York, New York  10021